Cellular Biomedicine Group, Inc. (CBMG)
| Market Cap | 352.75M |
| Revenue (ttm) | 322,950 |
| Net Income (ttm) | -54.80M |
| Shares Out | 19.43M |
| EPS (ttm) | -2.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $18.11 |
| Previous Close | $18.11 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 17.77 |
| Day's Range | 17.76 - 18.15 |
| Day's Volume | 21,747 |
| 52-Week Range | 11.51 - 19.27 |
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection w...
GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...
GAITHERSBURG, Md. and SHANGHAI, Nov. 9, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...
CBMG agreed to be taken private at $19.75 per share in cash. The transaction is subject to shareholder approval as well as CFIUS clearance.
NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating: Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal securities laws ...
NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc.
PHILADELPHIA, Aug. 14, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cellular Biomedicine Group, Inc.
NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) and its board of directors concerning the pro...
NEW YORK, Aug. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc.
NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Cell...
GAITHERSBURG, Md. and SHANGHAI, Aug.
New York, New York--(Newsfile Corp. - August 12, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cellular Biomedicine Group,...
GAITHERSBURG, Md. and SHANGHAI, Aug.
GAITHERSBURG, Md. and SHANGHAI, July 13, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug developmen...
GAITHERSBURG, Md. and SHANGHAI, June 30, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug developmen...
GAITHERSBURG, Md. and SHANGHAI, June 29, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development...
Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2020 Results - Earnings Call Transcript
Cellular Biomedicine Group's (CBMG) CEO Tony Liu on Q4 2019 Results - Earnings Call Transcript
Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q3 2019 Results - Earnings Call Transcript
Cellular Biomedicine Group, Inc. (CBMG) CEO Bizuo Liu on Q2 2019 Results - Earnings Call Transcript
Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2019 Results - Earnings Call Transcript
About CBMG
Cellular Biomedicine Group, a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor inf... [Read more...]
| Industry Biotechnology | |
| CEO Tony Liu | Employees 217 |
| Stock Exchange NASDAQ | Ticker Symbol CBMG |
Financial Performance
In 2019, CBMG's revenue was $339,920, an increase of 51.48% compared to the previous year's $224,403. Losses were -$49.98 million, 28.3% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for CBMG stock is "Hold" and the 12-month stock price forecast is 19.00.